Roche is shoring up its breast cancer franchise on both ends of the spectrum with FDA’s approval of Perjeta in very early, neoadjuvant breast cancer and new data showing Kadcyla is safe and effective at the back end of therapy in heavily pretreated, advanced patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?